|
|
|
|
|
|
|
|
|
|
press release
Founded in 2000, VBL is based in Or-Yehuda, Israel.
| Source: VBL Therapeutics
TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017.
- Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch a Phase 3 trial of VB-111 in Ovarian Cancer during the second half of 2017.
- Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018.
- VBL's novel immune-oncology target to be disclosed during 1H 2017....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.